NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Overview Fund Activity
Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

30 hedge funds and large institutions have $364K invested in Navidea Biopharmaceuticals Inc. in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 2 closing their positions.

Holders
30
Holders Change
+2
Holders Change %
+7.14%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
11
Closed
2
Calls
$1K
Puts
$6K
Net Calls
-$5K
Net Calls Change
-$4K

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$62K
2
Millennium Management
2
Millennium Management
New York
$33K
3
ACM
3
Allred Capital Management
Texas
$42.8K
4
Fidelity Investments
4
Fidelity Investments
Massachusetts
$260
5
TRCT
5
Tower Research Capital (TRC)
New York
$2K

Top Sellers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$74.5K
2
WAM
2
Warberg Asset Management
Illinois
$7.29K
3
Citadel Advisors
3
Citadel Advisors
Florida
$17.1K
4
VF
4
Virtu Financial
New York
$4K
5
PFO
5
Pathstone Family Office
New Jersey
$2.61K
Name Holding Trade Value Shares
Change 		Shares
Change %
KFS
26
Kelly Financial Services
Massachusetts
$13 – – –
BCMLT
27
Beacon Capital Management LLC (Tennessee)
Tennessee
$3 – – –
CTB
28
Country Trust Bank
Illinois
$2 +$2 +7 New
HF
29
HRT Financial
New York
– -$2K -12,614 Closed
PP
30
PDS Planning
Ohio
– -$2.22K -10,565 Closed
1
2